10-Q: Dynatronics Reports Q3 2024 Results: Revenue Declines Amid Cost-Cutting Efforts

Dynatronics Corporation experienced a decrease in revenue for the third quarter of 2024, while also reducing operating expenses.

Summary

• Dynatronics Corporation reported a net sales decrease of 17.1% to $7.658 million for the quarter ended March 31, 2024, compared to $9.236 million for the same period in 2023.
• The company's net sales for the nine months ended March 31, 2024, decreased by 21.8% to $25.161 million, down from $32.172 million in the prior year.
• Gross profit for the quarter decreased by 17.7% to $1.817 million, and for the nine-month period, it decreased by 33.3% to $5.943 million.
• Selling, general, and administrative expenses saw a significant reduction, decreasing by 30.3% to $2.389 million for the quarter and 32.9% to $7.656 million for the nine-month period.
• The company's net loss for the quarter was $668,000, an improvement from the $1.246 million loss in the same quarter of the previous year.
• For the nine months ended March 31, 2024, the net loss was $2.010 million, compared to a net loss of $2.592 million for the same period in 2023.
• The company has a line of credit with a balance of $2.352 million as of March 31, 2024, and a maximum availability of $7.5 million.
• As of May 3, 2024, there were 5,308,519 shares of the company's common stock outstanding.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant revenue declines offset by cost-cutting measures and improved net loss. The need for a line of credit and potential capital raise indicates financial challenges, resulting in a slightly negative sentiment.

Positives

• The company significantly reduced selling, general, and administrative expenses by 30.3% for the quarter and 32.9% for the nine-month period.
• Net loss improved by $578,000 for the quarter and $582,000 for the nine-month period compared to the same periods in the previous year.
• The company's cash position increased by $43,000 during the nine-month period.
• The company has access to a $7.5 million line of credit, with $2.352 million drawn as of March 31, 2024.

Negatives

• Net sales decreased by 17.1% for the quarter and 21.8% for the nine-month period.
• Gross profit decreased by 17.7% for the quarter and 33.3% for the nine-month period.
• The company experienced a decrease in gross profit margin from 27.7% to 23.6% for the nine month period.
• Inventories decreased by $1.219 million, indicating a potential reduction in future sales capacity.

Risks

• The company faces uncertainties in the broader economic environment, which could affect the global supply chain and customer demand.
• The company's ability to realize deferred income tax assets is uncertain, requiring a full valuation allowance.
• The company may need to raise additional funds through the sale of equity or debt securities, which may not be available on satisfactory terms.
• The company's financial covenants under the Loan Agreement require a minimum fixed charge coverage ratio of 1.0 to 1.0 if excess availability is less than $1,000,000 of the borrowing base.

Future Outlook

The company believes that its cash generated from operations, current capital resources, and proceeds of equity sales, if any, will provide sufficient liquidity to fund operations for the next 12 months, but there is no assurance that additional funds will not be required.

Management Comments

• Management's Discussion and Analysis of Financial Condition and Results of Operations is designed to provide a reader of our Unaudited Condensed Consolidated Financial Statements and Notes thereto that are contained in this quarterly report, with a narrative from the perspective of management.
• We believe that our cash generated from operations, current capital resources, and proceeds of equity sales, if any, under the ATM described below will provide sufficient liquidity to fund operations for the next 12 months.

Industry Context

The medical device industry is subject to various economic and regulatory factors, and Dynatronics' performance reflects the challenges of reduced demand and supply chain issues. The company's cost-cutting measures are in line with industry trends to improve profitability in a competitive market.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, the decrease in revenue and gross profit is a concern, as many medical device companies are experiencing growth in the post-pandemic environment.
• The reduction in SG&A expenses is a positive sign, but it needs to be balanced with the need to invest in sales and marketing to drive future growth.
• The company's reliance on a line of credit for operating capital is not uncommon in the industry, but it also indicates a need for improved cash flow management.
• Companies like DJO Global and Zimmer Biomet, which are larger players in the orthopedic and rehabilitation space, have reported varying results, but generally have stronger revenue growth and profitability.

Related Party Transactions

• The company leases facilities from shareholders and entities controlled by shareholders, with expenses totaling $332,857 and $249,366 for the three months ended March 31, 2024 and 2023, respectively, and $999,795 and $748,098 for the nine months ended March 31, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and gross profit, but may be encouraged by the cost-cutting measures and improved net loss.
• Employees may be affected by the reduction in salaries and benefits.
• Customers may experience changes in product availability or pricing due to the company's inventory management and supply chain adjustments.
• Creditors may be concerned about the company's reliance on a line of credit and potential need for additional capital.

Next Steps

• The company will continue to evaluate and take action to preserve adequate liquidity.
• The company may need to raise additional funds through the sale of equity or debt securities.
• The company will continue to monitor the broader economic environment and its impact on the business.

Key Dates

Keywords

medical devices, physical therapy, rehabilitation, orthopedics, pain management, athletic training, revenue, gross profit, operating expenses, net loss, line of credit, reverse stock split